
Paul R Walker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1916346/publications.pdf Version: 2024-02-01



DALLE D WALKED

#	Article	IF	CITATIONS
1	Untangling macrophage/microglia complexity in glioblastoma subtypes to elucidate the impact of CSF1R inhibition. Neuro-Oncology, 2022, 24, 598-600.	1.2	4
2	Glioma-Derived Extracellular Vesicles – Far More Than Local Mediators. Frontiers in Immunology, 2021, 12, 679954.	4.8	11
3	Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. , 2021, 9, e002181.		42
4	Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells. Communications Biology, 2021, 4, 718.	4.4	14
5	An update on actively targeted liposomes in advanced drug delivery to glioma. International Journal of Pharmaceutics, 2021, 602, 120645.	5.2	51
6	Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin). JCI Insight, 2021, 6, .	5.0	7
7	Cell surface CRP78: An emerging imaging marker and therapeutic target for cancer. Journal of Controlled Release, 2020, 328, 932-941.	9.9	55
8	An Experimentally Defined Hypoxia Gene Signature in Glioblastoma and Its Modulation by Metformin. Biology, 2020, 9, 264.	2.8	7
9	Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review. , 2020, 8, e001408.		100
10	Targeting self- and neoepitopes with a modular self-adjuvanting cancer vaccine. JCl Insight, 2019, 4, .	5.0	28
11	Harnessing Microglia and Macrophages for the Treatment of Glioblastoma. Frontiers in Pharmacology, 2019, 10, 506.	3.5	55
12	Peptides as cancer vaccines. Current Opinion in Pharmacology, 2019, 47, 20-26.	3.5	75
13	Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. Neuro-Oncology, 2019, 21, 923-933.	1.2	89
14	Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines. Cellular and Molecular Life Sciences, 2018, 75, 2887-2896.	5.4	33
15	Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. Oncolmmunology, 2018, 7, e1391972.	4.6	42
16	P01.122 Safety, immunogenicity and optimization of the IMA950 multipeptide vaccine combined with Poly-ICLC in newly diagnosed HLA-A2 malignant glioma patients. Neuro-Oncology, 2018, 20, iii260-iii260.	1.2	0
17	Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. Oncolmmunology, 2018, 7, e1501137.	4.6	120
18	<scp>ER</scp> –mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stemâ€like cells. EMBO Journal, 2017, 36, 1493-1512.	7.8	27

PAUL R WALKER

#	Article	IF	CITATIONS
19	Identification of a novel population of highly cytotoxic câ€Metâ€expressing CD8 ⁺ T lymphocytes. EMBO Reports, 2017, 18, 1545-1558.	4.5	22
20	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. Frontiers in Oncology, 2016, 6, 256.	2.8	39
21	Glioma Stemlike Cells Enhance the Killing of Glioma Differentiated Cells by Cytotoxic Lymphocytes. PLoS ONE, 2016, 11, e0153433.	2.5	8
22	Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing. PLoS ONE, 2016, 11, e0162105.	2.5	17
23	Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants. Molecular Therapy, 2016, 24, 1675-1685.	8.2	29
24	Cell-penetrating peptides—the Swiss Army knife of cancer vaccines. Oncolmmunology, 2016, 5, e1095435.	4.6	5
25	The CD40/CD40L axis in glioma progression and therapy. Neuro-Oncology, 2015, 17, 1428-1430.	1.2	12
26	Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell–Mediated Antitumor Immunity. Cancer Research, 2015, 75, 3020-3031.	0.9	50
27	Immunotherapy for Glioma: From Illusion to Realistic Prospects?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 51-59.	3.8	5
28	Getting by with a little help from the right CD4 ⁺ T cells. Oncolmmunology, 2013, 2, e25772.	4.6	4
29	Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain, 2012, 135, 1042-1054.	7.6	192
30	Homing Phenotypes of Tumor-Specific CD8 T Cells Are Predetermined at the Tumor Site by Crosspresenting APCs. Immunity, 2005, 22, 175-184.	14.3	209
31	T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Research Reviews, 2003, 42, 97-122.	9.0	77
32	Cutting Edge: Cross-Presentation as a Mechanism for Efficient Recruitment of Tumor-Specific CTL to the Brain. Journal of Immunology, 2003, 171, 2187-2191.	0.8	58
33	All in the head: obstacles for immune rejection of brain tumours. Immunology, 2002, 107, 28-38.	4.4	53